Kezar Life Sciences(US:KZR)2025-11-12 21:07Financial Position - As of September 30, 2025, Kezar Life Sciences, Inc. reported a preliminary cash, cash equivalents, and marketable securities position of $90.2 million[8]. Regulatory Updates - The company announced a regulatory update on its zetomipzomib program in autoimmune hepatitis[8]. - The press release regarding these updates was issued on October 16, 2025[8]. Strategic Alternatives - Kezar Life Sciences, Inc. is exploring strategic alternatives as part of its future growth strategy[8]. Rights Agreement - The Rights Agreement was amended to extend the Final Expiration Date to the day following the certification of the voting results of the Company's 2026 annual meeting of stockholders[11]. - If stockholders approve the Rights Agreement at the 2026 meeting, the expiration will extend to the day following the certification of the 2027 meeting results[11]. - The Rights Agreement remains unmodified and in full force and effect[11]. Company Classification and Listing - The company is classified as an emerging growth company under the Securities Act of 1933[6]. - The company is listed on The Nasdaq Stock Market LLC under the symbol KZR[5]. Report Signing - The report was signed by Marc L. Belsky, Chief Financial Officer and Secretary, on October 16, 2025[18].